Hitoshi Tsuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hitoshi Tsuda has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Osamu Matsubara
Department of Basic Pathology, National Defense Medical College, Saitama, Japan
4 shared publicationsSohei Yamamoto
Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
4 shared publicationsKosuke Miyai
Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
3 shared publicationsSeiichi Tamai
Department of Basic Pathology, National Defense Medical College, Tokorozawa, Japan
3 shared publicationsTomohiko Asano
National Defense Medical College (Japan)
3 shared publications- Akio Horiguchi
Center for Trauma, Burn and Tactical Medicine National Defense Medical College Hospital Saitama Japan
2 shared publications
Latest Publications
- 3 March 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10064, 100642
Possibility of transrectal photoacoustic imaging-guided biopsy for detection of prostate cancer
A transrectral ultrasonography (TRUS) guided prostate biopsy is mandatory for histological diagnosis in patients with an elevated serum prostate-specific antigen (PSA), but its diagnostic accuracy is not satisfactory; therefore, a considerable number of patients are forced to have an unnecessary repeated biopsy.Photoacoustic (PA) imaging has the ability to visualize the distribution of hemoglobin clearly. Thus, there is the potential to acquire different maps of small vessel networks between cancerous and normal tissue. We developed an original TRUS-type PA probe consisting of a microconvex array transducer with an optical illumination system providing coregistered PA and ultrasound images. The purpose of this study is to demonstrate the clinical possibility of a transrectral PA image.The prostate biopsy cores obtained by transrectal systemic biopsies under TRUS guidance were stained with HE staining and anti-CD34 antibodies as a marker of the endothelium of the blood vessel in order to find a pattern in the map of a small vessel network, which allows for imaging-based identification of prostate cancer. We analyzed the association of PA signal patterns, the cancer location by a magnetic resonance imaging (MRI) study, and the pathological diagnosis with CD34 stains as a prospective intervention study.In order to demonstrate the TRUS-merged-with-PA imaging guided targeted biopsy combined with a standard biopsy for capturing the clinically significant tumors, we developed a puncture needle guide attachment for the original TRUS-type PA probe. © (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
- 3 March 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10064, 100642
Possibility of transrectal photoacoustic imaging-guided biopsy for detection of prostate cancer
A transrectral ultrasonography (TRUS) guided prostate biopsy is mandatory for histological diagnosis in patients with an elevated serum prostate-specific antigen (PSA), but its diagnostic accuracy is not satisfactory; therefore, a considerable number of patients are forced to have an unnecessary repeated biopsy.Photoacoustic (PA) imaging has the ability to visualize the distribution of hemoglobin clearly. Thus, there is the potential to acquire different maps of small vessel networks between cancerous and normal tissue. We developed an original TRUS-type PA probe consisting of a microconvex array transducer with an optical illumination system providing coregistered PA and ultrasound images. The purpose of this study is to demonstrate the clinical possibility of a transrectral PA image.The prostate biopsy cores obtained by transrectal systemic biopsies under TRUS guidance were stained with HE staining and anti-CD34 antibodies as a marker of the endothelium of the blood vessel in order to find a pattern in the map of a small vessel network, which allows for imaging-based identification of prostate cancer. We analyzed the association of PA signal patterns, the cancer location by a magnetic resonance imaging (MRI) study, and the pathological diagnosis with CD34 stains as a prospective intervention study.In order to demonstrate the TRUS-merged-with-PA imaging guided targeted biopsy combined with a standard biopsy for capturing the clinically significant tumors, we developed a puncture needle guide attachment for the original TRUS-type PA probe. © (2017) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
- 15 March 2016
- Published by SPIE-Intl Soc Optical Eng
- p. 970852-970852-6
Comparison of transrectal photoacoustic, Doppler, and magnetic resonance imaging for prostate cancer detection
- 15 March 2016
- Published by SPIE-Intl Soc Optical Eng
- p. 970852-970852-6
Comparison of transrectal photoacoustic, Doppler, and magnetic resonance imaging for prostate cancer detection
- Open Access
- 6 February 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 5
A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer
Ki67 is widely used in order to distinguish the “A” and “B” subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index (LI), and uni- and multivariate analyses were performed. Division of the patients based on the immunohistochemistry results into favorable- (low Ki67 LI, p53-negative) and unfavorable- (high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-Meier's curves of both disease-free (PP=0.0007). These differences were much more distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor by multivariate analysis. These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for management of patients with HR-positive breast cancer.
- 6 February 2013
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 13 (1) , 5
Open AccessA simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer
Ki67 is widely used in order to distinguish the “A” and “B” subtypes of luminal-type breast cancer. This study aimed to validate the prognostic value of adding p53 to Ki67 for characterizing luminal-type breast cancer. Immunostaining for Ki67, p53, and the molecular markers HER2, CK5/6, CK14, EGFR, FOXA1, GATA3, and P-cadherin was examined hormone receptor (HR)-positive cancer tissues from 150 patients. The prognostic value of an immunohistochemical panel comprising Ki67 and p53 was compared with that of the single Ki67 labeling index (LI), and uni- and multivariate analyses were performed. Division of the patients based on the immunohistochemistry results into favorable- (low Ki67 LI, p53-negative) and unfavorable- (high Ki67 LI and/or p53-positive) phenotype groups yielded distinctly different Kaplan-Meier's curves of both disease-free (PP=0.0007). These differences were much more distinct than those between the corresponding low Ki67 LI vs. high Ki67LI curves. While the prognostic values of the other molecular markers were not significant, combined Ki67-p53 status was an independent prognostic factor by multivariate analysis. These data indicate that an immunohistochemical panel comprising Ki67 and p53 is a practical tool for management of patients with HR-positive breast cancer.
- Open Access
- 8 May 2012
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (10) , 1260-1265
Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
- 8 May 2012
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (10) , 1260-1265
Open AccessCombination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
- 15 March 2012
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 3 (6) , 931-936
Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma
Recent studies indicate the clinical significance of the cellular localization of epidermal growth factor receptor (EGFR) in a variety of cancer types. Internalization of activated EGFR is reported to be closely associated with patient prognosis. This study investigated the clinical significance of the immunohistochemical localization of EGFR in patients with metastatic pancreatic cancers compared to those with surgically resected pancreatic cancers. Using 44 surgically resected primary pancreatic cancers and 40 primary or metastatic tumors from 20 autopsied patients with far advanced pancreatic cancers, the incidence of membranous and cytoplasmic EGFR overexpression was compared between primary tumors and far advanced tumors by immunohistochemistry using the Dako EGFR pharmDx™ kit, a global standard kit for EGFR assay. In the 44 surgically resected cancers, 13 (30%) exhibited membranous overexpression of EGFR, comprising 1 case (2%) with score 3+ and 12 cases (27%) with score 2+ and 10 (23%) exhibited cytoplasmic overexpression of EGFR. In the 40 tumors at a far advanced stage, the percentage of samples exhibiting positivity for membranous and cytoplasmic EGFR overexpression was 48% (19 of 40) comprising 7 (18%) with score 2+ and 12 (30%) with score 3+ and 33% (13 of 40), respectively. The far advanced tumors tended to show membranous and cytoplasmic EGFR overexpression more frequently than the surgically resected tumors, although the difference was not significant. These findings suggest that membranous and cytoplasmic overexpression of EGFR may be indicative of the potential aggressiveness of pancreatic cancers.
- 15 March 2012
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 3 (6) , 931-936
Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma
Recent studies indicate the clinical significance of the cellular localization of epidermal growth factor receptor (EGFR) in a variety of cancer types. Internalization of activated EGFR is reported to be closely associated with patient prognosis. This study investigated the clinical significance of the immunohistochemical localization of EGFR in patients with metastatic pancreatic cancers compared to those with surgically resected pancreatic cancers. Using 44 surgically resected primary pancreatic cancers and 40 primary or metastatic tumors from 20 autopsied patients with far advanced pancreatic cancers, the incidence of membranous and cytoplasmic EGFR overexpression was compared between primary tumors and far advanced tumors by immunohistochemistry using the Dako EGFR pharmDx™ kit, a global standard kit for EGFR assay. In the 44 surgically resected cancers, 13 (30%) exhibited membranous overexpression of EGFR, comprising 1 case (2%) with score 3+ and 12 cases (27%) with score 2+ and 10 (23%) exhibited cytoplasmic overexpression of EGFR. In the 40 tumors at a far advanced stage, the percentage of samples exhibiting positivity for membranous and cytoplasmic EGFR overexpression was 48% (19 of 40) comprising 7 (18%) with score 2+ and 12 (30%) with score 3+ and 33% (13 of 40), respectively. The far advanced tumors tended to show membranous and cytoplasmic EGFR overexpression more frequently than the surgically resected tumors, although the difference was not significant. These findings suggest that membranous and cytoplasmic overexpression of EGFR may be indicative of the potential aggressiveness of pancreatic cancers.
- 1 January 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 25 (1) , 122-130
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
- 1 January 2012
- Published by Elsevier in Laboratory Investigation
- Vol. 25 (1) , 122-130
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
- 1 August 2011
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (8) , 1146-1155
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
- 1 August 2011
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (8) , 1146-1155
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
- Open Access
- 21 June 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (3) , R66
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3
Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that of vascular endothelial growth factor receptors (VEGFRs). Although sunitinib is a clinically available angiogenesis inhibitor, its effects on lymphangiogenesis and lymph node metastasis remain unclear. The purpose of this study was to investigate the effects of sunitinib on vascular endothelial growth factor receptor 3 (VEGFR-3) and a related event, lymphangiogenesis.
- 21 June 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (3) , R66
Open AccessSunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3
Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that of vascular endothelial growth factor receptors (VEGFRs). Although sunitinib is a clinically available angiogenesis inhibitor, its effects on lymphangiogenesis and lymph node metastasis remain unclear. The purpose of this study was to investigate the effects of sunitinib on vascular endothelial growth factor receptor 3 (VEGFR-3) and a related event, lymphangiogenesis.
- 12 May 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (3) , 793-805
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR−/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2−) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR−/HER2+ subtype (21%) than for the HR+/HER2− subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR−/HER2+ subtype than in the HR+/HER2− subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.
- 12 May 2011
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (3) , 793-805
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR−/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2−) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR−/HER2+ subtype (21%) than for the HR+/HER2− subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR−/HER2+ subtype than in the HR+/HER2− subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.
- Open Access
- 21 October 2010
- Published by Springer Nature in Breast Cancer
- Vol. 18 (1) , 1-2
Radiofrequency ablation therapy for primary breast cancer: expectations and problems as a novel breast conservation therapy
- 21 October 2010
- Published by Springer Nature in Breast Cancer
- Vol. 18 (1) , 1-2
Open AccessRadiofrequency ablation therapy for primary breast cancer: expectations and problems as a novel breast conservation therapy